The psychedelic compound-based clinical stage drug research and development sector is Up 13.6% MTD and is now Up 26.6% YTD. This article analyzes the performance of the 6 largest stocks in the Psychedelic Drug Stocks Index over those two time periods in descending order.

1. Seelos (SEEL): Up 31.7% MTD; Up 143.1% YTD
   • focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
   • Market Capitalization: $192M
   • July 21st Stock Price: $1.58
   • current short interest: 4.7%
   • Read: Seelos Addressing Significant And Unmet Needs In Rare Psychiatric And Movement Disorders
2. Mind Medicine (MNMD): Up 30.3% MTD; Up 118.3% YTD
   • is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Market Capitalization: $179M
   • July 21st Stock Price: $4.65
   • current short interest: 9.4%
   • Read: MindMed: Researching LSD And MNMA To Treat Neurological Diseases
3. Atai (ATAI): Up 21.5% MTD; Down 19.0% YTD
   • focused on the use of ketamine*, DMT* and ibogaine*.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Market Capitalization: $347M
   • July 21st Stock Price: $2.09
   • current short interest: 3.4%
   • Read: Atai Life Sciences: Long On Money; Short On Success
4. GH Research (GHRS): Up 10.4% MTD; Up 37.3% YTD
   • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine,
   • Market Capitalization: $681M
   • July 21st Stock Price: $13.10
   • current short interest: 10.3%
   • Read: GH Resources: Focus On Treatment-Resistant Depression Paying Off 
5. Compass Pathways (CMPS): Up 8.2% MTD; Up 14.7% YTD
   • is focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin and
   • Market Capitalization: $409M
   • July 21st Stock Price: $8.96
   • current short interest: 9.9% - A high short interest signals that investors have become more bearish and may be getting ready to sell and, as such, that it may be time to liquidate a long position.
6. Incannex Healthcare (IXHL): Up 7.7% MTD; Down 29.6% YTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Market Capitalization: $117M (US)
   • July 21st Stock Price: $1.97
   • has announced that it intends to relocate to the United States, with plans to eventually delist from the ASX and switch to the NASDAQ board as it believes the US market is more receptive to pharmaceutical programs.
   • current short interest: NA
   • Read: Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.
 

Summary

The munKNEE Psychedelic Drug Stocks Index is Up 13.6% MTD and is now Up 26.6% YTD. If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks. It is Up 8.2% MTD and is now Up 7.0% YTD.

More By This Author:

Largest Cannabis LPs Down 5% This Week
Largest Cannabis MSOs Down 8.5% So Far This Week
These 10 "Penny" AI Stocks Are Up 51% With Lots Of Room To Run